Sorrento Initiates Enrollment in P-II MSC-COV-202BR Study for the Treatment of Acute Respiratory Distress due to COVID-19 in Brazil

September 7, 2021 Auto Bot Clinical Trials 0

Shots:

  • The first patient has been enrolled at the first site in P-II MSC-COV-202BR efficacy study evaluates COVI-MSC vs PBO in 100 patients with COVID-19-induced ARD or ARDS in Brazil
  • The primary objective of the study is to evaluate the efficacy of COVI-MSCs in patients with COVID-19-induced ARD or ARDS
  • Additionally, the company plans to start the enrollment for two additional P-III studies with COVI-MSC across multiple sites in the US & Brazil

Click here to­ read full press release/ article | Ref: Sorrento | Image: City Biz

The post Sorrento Initiates Enrollment in P-II MSC-COV-202BR Study for the Treatment of Acute Respiratory Distress due to COVID-19 in Brazil first appeared on PharmaShots.